Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Karen Salomon-Escoto

General Rheumatology · UMMHC

View

Dr. Jeffrey Sparks

General Rheumatology · PHS

View

Dr. Amanda Nelson

General Rheumatology · UNC

View

Dr. Simon Helfgott

General Rheumatology · BWH

View

Dr. Paul Sufka

General Rheumatology · TCO

View

Dr. Ozlem Pala

General Rheumatology · U Miami

View

Dr. Medha Barbhaiya

General Rheumatology · HSS

View

Dr. Anisha Dua

Vasculitis · NU

View

Dr. Sara Tedeschi

Crystal-Related Diseases · BWH

View

Dr. Alfred Kim

Lupus · WUSTL

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    NGDr. Nilasha Ghosh
    Leading Voice

    Dr. Nilasha Ghosh

    Rheumatology · General Rheumatology
    Hospital for Special Surgery
    nilasha

    Research

    Arthroplasty Joint Histology and Surgical Outcomes in Patients on Immune Checkpoint Inhibitors: A Single-Center Case Series

    2026

    Via The Journal of Rheumatology

    Research

    Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study

    2026

    Via Annals of the Rheumatic Diseases

    Research

    Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study

    2026

    Via Journal for Immunotherapy of Cancer

    Research

    Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma [Preprint]

    2025

    Via bioRxiv

    Research

    Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study

    2025

    Via Rheumatology (Oxford, England)

    Research

    Necrotizing and Nonnecrotizing Granulomatous Reactions in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Literature Review

    2025

    Via The Journal of Rheumatology

    Research

    Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis

    2025

    Via Arthritis Care & Research

    Research

    Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma

    2025

    Via JCI Insight

    Research

    Evolving and evaluating the OMERACT fellows program: insights and implications from OMERACT 2023 fellows

    2024

    Via Seminars in Arthritis and Rheumatism

    Research

    The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review

    2024

    Via Rheumatic Diseases Clinics of North America

    Research

    Prioritising domains of glucocorticoid therapy to measure in trials: Results from a modified delphi exercise from the OMERACT glucocorticoid impact working group

    2024

    Via Seminars in Arthritis and Rheumatism

    Research

    Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis

    2023

    Via RMD Open

    Research

    Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

    2023

    Via Annals of the Rheumatic Diseases

    Research

    Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measure

    2023

    Via Rheumatology (Oxford, England)

    Research

    Immune checkpoint inhibitor-associated systemic lupus erythematosus with pleural effusion, hypothyroidism and medium vessel vasculopathy

    2022

    Via BMJ Case Reports